Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc. (SXTP)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: A specialty pharmaceutical company focused on infectious diseases. Its primary commercial product is Arakoda (tafenoquine), approved for malaria prevention. The company is actively repositioning tafenoquine for the treatment of babesiosis (tick-borne disease) and fungal infections, and evaluating Celgosivir for viral diseases. The company operates with a small virtual management team and relies on third-party manufacturing.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Product Revenue | $607,574 | $253,573 |
| Research Revenue | $73,771 | $0 |
| Total Net Revenue | $681,345 | $253,573 |
| Gross Profit | $222,809 | ($220,977) |
| Gross Margin | 36.7% | (87.2%) |
| Operating Expenses | $10,011,511 | $4,933,606 |
| Net Loss (Attributable to 60P) | ($7,947,107) | ($3,765,702) |
| Cash and Cash Equivalents | $1,659,353 | $2,142,485 |
| Short-Term Investments | $1,728,472 | $0 |
| Total Debt (SBA Loan) | $155,891 | $159,023 |
Note: The company reported a significant increase in Research & Development expenses ($4.99M vs $0.69M) driven by share-based payments to vendors and costs related to the babesiosis clinical trial.
Material Changes vs. Prior Period
- Revenue Growth: Product revenue increased 140% year-over-year, driven by a 214% increase in box sales (5,119 boxes in 2024 vs. 1,632 in 2023). Growth is attributed to organic prescribing for babesiosis in the Lyme disease community.
- Margin Improvement: Gross margin turned positive (36.7%) from a loss (87.2%) due to higher sales volume absorbing fixed costs and a significant reduction in inventory write-downs ($22k in 2024 vs. $191k in 2023).
- Capital Structure: The company executed two reverse stock splits (1:12 in August 2024 and 1:5 in February 2025) to maintain Nasdaq listing compliance. All share data in the filing is retroactively adjusted.
- Financing Activity: The company raised capital through multiple offerings in late 2024 and early 2025, including a September 2024 private placement, an At-The-Market (ATM) offering, and registered direct offerings in January and February 2025.
Guidance, Outlook, and Risks
Outlook and Strategy
- Commercialization: Launched a promotional pilot for Arakoda in late 2024 to increase awareness and drive sales for malaria prevention.
- Clinical Pipeline:
- Babesiosis: Initiated a Phase II study for chronic babesiosis (enrollment expected Q3 2025) and an expanded access study. First patient enrolled in expanded access study in January 2025.
- Fungal Infections: Planning animal studies for parenteral tafenoquine against Candida.
- Celgosivir: Evaluating non-clinical models for respiratory viruses (RSV, COVID-19) pending funding.
- Liquidity: Management estimates sufficient funds to remain viable through August 31, 2025, based on current cash, recent financing proceeds (~$7M total from late 2024/early 2025 offerings), and sales growth. This excludes costs for the expanded access study.
Risks and Contingencies
- Going Concern: Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional capital. The financial statements do not include adjustments that might be necessary if the company cannot continue.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, including inadequate policy design, lack of documentation, and insufficient segregation of duties. Remediation is expected in the first half of 2025.
- Cybersecurity: The company currently lacks formalized cybersecurity measures or a dedicated team, posing a risk to data integrity and operations.
- Supply Chain: Reliance on a sole vendor for the active pharmaceutical ingredient (API). The FDA authorized the importation of Kodatef (Australian version) in February 2025 to mitigate potential shortages.
- Contingent Liability: A $10 million contingent milestone payment is due to Knight Therapeutics upon the sale of Arakoda or a Change of Control.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "August 31, 2025" liquidity estimate against actual cash burn rates and the timing of the planned babesiosis clinical trials.
- Revenue Sustainability: Confirm if the 214% sales growth is sustainable or driven by one-time inventory purchases by distributors, and monitor the success of the new promotional pilot.
- Internal Control Remediation: Monitor the progress of remediation efforts for the identified material weaknesses in internal controls to ensure future financial reporting reliability.
- Clinical Trial Progress: Track enrollment and interim data for the Phase II chronic babesiosis study (NCT06656351) and the expanded access study (NCT06478641).
- Dilution Risk: Assess the impact of the numerous warrants issued in the January and February 2025 offerings on future share count and potential dilution upon exercise.